abt-719 hydrochloride

ABT-719 is a 2-pyridinone antimicrobial agent that is more effective against Enterococcus faecalis strains than ciprofloxacin and vancomycin, which showed resistance to ciprofloxacin and vancomycin covering a range of MIC.

ABT-418 hydrochloride is a selective agonist of nAChRs with cognitive enhancing and anxiolytic activities. It activates cholinergic channel and can be used for the research of Alzheimer's disease.

Potent non-nucleoside adenosine kinase inhibitor (IC50 = 1.7 nM), selective over other sites of adenosine interaction (A1, A2A and A3 receptors, adenosine transporter and adenosine deaminase). Displays oral activity in animal models of pain and inflammation.

ABT-702 hydrochloride effectively inhibits adenosine kinase, exhibiting an IC50 value of 1.7 nM [1] [2].

ABT-491 hydrochloride is an active platelet activator receptor (PAF-R) antagonist with good selectivity and oral administration.

ABT-639 hydrochloride is a selective, novel T-type Ca2+ channel blocker.

ABT-751 (E7010) hydrochloride is a novel sulfonyl anti-mitotic compound and a tubulin binder with high oral bioavailability. This agent binds to the colchicine site on β-tubulin, inhibiting the polymerization of tubulin which results in cell cycle arrest at the G2 M phase and induces apoptosis, effectively preventing cell division. Additionally, ABT-751 (E7010) hydrochloride induces autophagy by inhibiting the AKT MTOR signaling pathway. It exhibits significant inhibitory effects against various types of cancer cells, including lung, stomach, colon, and breast cancer.